文献速递妇科

妇科肿瘤一期临床试验少数族裔参与度三十年不平等

Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity.
PubMed 文献 · Gynecol Oncol · 2020-03-13

该研究分析1985至2018年妇科肿瘤一期临床试验文章357篇(9492例受试者),其中84篇(2483例)报告种族分布:白人1950例(79%)、黑人140例(5%)、其他393例(16%)。黑人参与度低于基于年龄调整发病率的预期,卵巢癌、子宫内膜癌和宫颈癌的发病率与入组比分别为18.5、3.6和6.8(均P < .001),且1995-1999年至2015-2018年黑人受试者比例下降1.8倍(P < .025)。

要点

  • 妇科肿瘤一期试验中黑人参与度显著低于预期,无研究达到预期入组。
  • 卵巢癌、子宫内膜癌和宫颈癌的发病率与入组比分别为18.5、3.6和6.8(均P < .001)。
  • 1995-1999年至2015-2018年黑人受试者比例下降1.8倍(P < .025)。

核心结论

  • 妇科肿瘤一期临床试验存在显著的种族参与不足,黑人受试者入组低于基于发病率的预期。
  • 需要增加黑人受试者入组以实现种族公平。

研究设计与样本

  • 研究为对1985至2018年同行评议发表的妇科肿瘤一期临床试验文章的手动回顾分析。
  • 共纳入357篇文章,总计9492例受试者,其中84篇(2483例)报告了种族分布。
  • 基于美国疾病控制与预防中心年龄调整癌症发病率计算种族参与的预期与观察比值。

主要发现

  • 84篇报告种族分布的文章中,白人1950例(79%)、黑人140例(5%)、其他393例(16%)。
  • 84项试验中46项(55%)其他非白人种族入组超过黑人。
  • 黑人入组低于预期:卵巢癌发病率与入组比18.5(P < .001),子宫内膜癌3.6(P < .001),宫颈癌6.8(P < .001)。
  • 无一期研究达到黑人预期入组。
  • 黑人受试者比例从1995-1999年的8/70(11%)下降至2015-2018年的55/892(6%),下降1.8倍(P < .025)。

临床怎么用

  • 妇产科医生应关注一期临床试验中少数族裔的代表性不足,积极鼓励黑人患者参与。
  • 在临床试验设计和招募中需采取措施提高黑人受试者入组,以促进种族公平。

局限性

  • 仅23%的文章(84/357)报告了种族分布,数据可能不完整。
  • 研究为回顾性分析,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: It is important to develop effective therapies in minorities to ensure equity in cancer care. Underrepresentation of minorities in early phase trials may cause therapies that are effective only in majority populations. We evaluated minority participation in gynecologic oncology phase 1 clinical trials. METHODS: In peer-reviewed published articles of gynecologic oncology phase 1 clinical trials from years 1985 to 2018, we manually abstracted racial distribution of enrolled participants, cancer type, and year published. We calculated expected and observed ratios of racial participation on the basis of age-adjusted cancer incidence for race from the United States Centers for Disease Control and Prevention. RESULTS: We identified 357 articles of phase 1 trials (total, 9492 participants), including 213 articles on ovarian cancer (60%). Racial distribution of participants was available in 84 articles (23%) that included 2483 participants (26%): 1950 white (79%), 140 black (5%), and 393 other participants (16%). Other nonwhite races exceeded black enrollment in 46 of 84 trials (55%) that listed race. Enrollment of black participants was less than expected from disease incidence for ovarian (incidence-to-enrollment ratio, 18.5; P < .001), endometrial (3.6; P < .001), and cervical cancer (6.8; P < .001). No phase 1 study met expected enrollment for black participants. Frequency of black participants decreased 1.8-fold from 1995 to 1999 (8 of 70 participants [11%]) to 2015-2018 (55 of 892 participants [6%]; P < .025). CONCLUSIONS: Major racial underrepresentation exists in gynecologic oncology phase 1 clinical trials. Enrollment of more black participants is needed to achieve racial equity.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Awad E, Paladugu R, Jones N, et al. Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity. Gynecol Oncol. 2020. PMID: 32173047. doi:10.1016/j.ygyno.2020.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。